Profile

Contact Details

Phone: +64 3 479 3453
Email: glen.reid@otago.ac.nz

University Links

Position

Senior Lecturer

Department

Department of Pathology (Dunedin)

Research summary

Translational cancer research

Teaching

Research student supervision: 2 Summer Studentships, 2 Honours students, 1 PhD, 1 MSc candidate
Lecturer for PATH 201, PATH 301 and PATH 302
Tutor for ELM2 (Pathology and Chemical Pathology)

Memberships

Member, International Association for the Study of Lung Cancer (IASLC), 2012-present
Member, International Mesothelioma Interest Group (iMig), 2011-present
Associate member, Maurice Wilkins Centre for Molecular Discovery (MWC) 2018–present
Member, New Zealand Society for Oncology (NZSO) 2018–present

Research

My research focuses on two main areas.

Understanding the phenomenon of drug tolerance in cancer

Many melanoma and lung cancer patients frequently show dramatic responses when treated with targeted therapies (kinase inhibitors). Unfortunately, these responses are short-lived and patients relapse with resistant tumours. Together with Dr Cath Drummond, I am investigating the ability of cancer cells to shift to drug-tolerant states, allowing their initial survival – and eventual resistance – following treatment with targeted therapies. This work is funded by a Marsden project grant.

Translational research into the asbestos-related cancer mesothelioma

Mesothelioma is a rare but very aggressive cancer with one of the lowest 5-year survival rates. There are no early detection markers and few effective therapies. My work focuses on the role of microRNAs in the biology of MPM and encompasses biomarker discovery and novel therapeutic approaches. This research is a continuation of the work I led in Sydney which identified tumour and blood markers and resulted in a phase I clinical trial of microRNA replacement therapy (NCT 02369198).

Research Projects

There are several research projects available, ranging from honours and master’s to PhD. Interested graduate and postgraduate students are encouraged to make contact to further discuss these projects.

New nucleic acid-based drugs for cancer therapy. Level: honours / master's
The impact of KRAS expression levels on the emergence of drug tolerance in lung cancer. Level: honours / master’s
Manipulating microRNAs to manage mesothelioma. Level: honours / master’s
Too much of a good thing? A potential role for untranslated p53 mRNA in cancer biology. Level: honours / master’s
A phoenix from the ashes: The role of dying cancer cells in the emergence of drug tolerance. Level: honours / master’s
Inhibiting adaptive mutability to prevent the emergence of drug resistance. Level: honours / master’s

Publications

Davis, W. J. H., Drummond, C. J., Diermeier, S., & Reid, G. (2024). The potential links between lncRNAs and drug tolerance in lung adenocarcinoma. Genes, 15, 906. doi: 10.3390/genes15070906 Journal - Research Other

van Zandwijk, N., Frank, A. L., Reid, G., Røe, O. D., & Amos, C. I. (2024). Asbestos-related lung cancer: An underappreciated oncological issue. Lung Cancer, 194, 107861. doi: 10.1016/j.lungcan.2024.107861 Journal - Research Article

Ezegbogu, M., Wilkinson, E., Reid, G., Rodger, E. J., Brockway, B., Russell-Camp, T., Kumar, R., & Chatterjee, A. (2024). Cell-free DNA methylation in the clinical management of lung cancer. Trends in Molecular Medicine. Advance online publication. doi: 10.1016/j.molmed.2024.03.007 Journal - Research Other

Schelch, K., Eder, S., Zitta, B., Phimmachanh, M., Emminger, D., Wenninger-Weinzierl, A., … Reid, G., & Grusch, M. (2024). YB-1 regulates mesothelioma cell migration via Snail but not EGFR, MMP1, EPHA5 or PARK2. Molecular Oncology, 18(4), 815-831. doi: 10.1002/1878-0261.13367 Journal - Research Article

Reid, G. (2023). Modulating microRNA expression to treat thoracic cancer [Invited]. Proceedings of the New Zealand Controlled Release Society (NZCRS) Symposium. Retrieved from http://nzcrs.org.nz/#/home Conference Contribution - Published proceedings: Abstract

2024

Journal - Research Article

Journal - Research Other

Davis, W. J. H., Drummond, C. J., Diermeier, S., & Reid, G. (2024). The potential links between lncRNAs and drug tolerance in lung adenocarcinoma. Genes, 15, 906. doi: 10.3390/genes15070906

2023

Journal - Research Article

Ahmadzada, T., Vijayan, A., Vafaee, F., Azimi, A., Reid, G., Clarke, S., … Hosseini-Beheshti, E. (2023). Small and large extracellular vesicles derived from pleural mesothelioma cell lines offer biomarker potential. Cancers, 15, 2364. doi: 10.3390/cancers15082364

Conference Contribution - Published proceedings: Abstract

2022

Journal - Research Article

Johnson, B., Zhuang, L., Rath, E. M., Yuen, M. L., Cheng, N. C., Shi, H., … Reid, G., & Cheng, Y. Y. (2022). Exploring microRNA and exosome involvement in malignant pleural mesothelioma drug response. Cancers, 14(19), 4784. doi: 10.3390/cancers14194784

Journal - Research Other

Zheng, Q., Reid, G., Eccles, M. R., & Stayner, C. (2022). Non-coding RNAs as potential biomarkers and therapeutic targets in polycystic kidney disease [Mini review]. Frontiers in Physiology, 13, 1006427. doi: 10.3389/fphys.2022.1006427

van Zandwijk, N., Rasko, J. E. J., George, A. M., Frank, A. L., & Reid, G. (2022). The silent malignant mesothelioma epidemic: A call to action. Lancet Oncology, 23, 1245-1248. doi: 10.1016/S1470-2045(22)00269-8

2021

Journal - Research Article

Reid, G., Klebe, S., van Zandwijk, N., & George, A. M. (2021). Asbestos and zeolites: From A to Z via a common ion. Chemical Research in Toxicology, 34, 936-951. doi: 10.1021/acs.chemrestox.0c00286

McDougall, L. I., Powell, R. M., Ratajska, M., Lynch-Sutherland, C. F., Hossain, S. M., Wiggins, G. A. R., … Motwani, J., Macaulay, E. C., Reid, G., Walker, L. C., … Eccles, M. R. (2021). Differential expression of BARD1 isoforms in melanoma. Genes, 12(2), 320. doi: 10.3390/genes12020320

Conference Contribution - Published proceedings: Abstract

Kirschner, M., Orlowski, V., Opitz, I., & Reid, G. (2021). Diagnostic potential of novel mesothelioma-specific microRNAs. Journal of Thoracic Oncology, 16(10 Suppl.), (pp. S956). doi: 10.1016/j.jtho.2021.08.228

Elgar, K., Drummond, C. J., & Reid, G. (2021). Using fluorescence-activated cell sorting to characterise drug-tolerant A375 melanoma populations. New Zealand Medical Journal, 134(1543), (pp. 155-156). Retrieved from https://www.nzma.org.nz/journal

2020

Journal - Research Article

Johnson, T. G., Schelch, K., Blair, K., Marzec, K. A., Kennerson, M., Grusch, M., Reid, G., & Burgess, A. (2020). YB-1 knockdown inhibits the proliferation of mesothelioma cells through multiple mechanisms. Cancers, 12(8), 2285. doi: 10.3390/cancers12082285

Ahmadzada, T., Cooper, W. A., Holmes, M., Mahar, A., Westman, H., Gill, A. J., … Reid, G., … Kao, S. (2020). Retrospective evaluation of the use of pembrolizumab in malignant mesothelioma in a real-world Australian population. JTO Clinical & Research Report, 1(4), 1-15. doi: 10.1016/j.jtocrr.2020.100075

Ahmadzada, T., Kao, S., Reid, G., Clarke, S., Grau, G. E., & Hosseini-Beheshti, E. (2020). Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review. Critical Reviews in Oncology/Hematology, 150, 102949. doi: 10.1016/j.critrevonc.2020.102949

Kruse, H. V., Tran, C. T. H., van Zandwijk, N., Suchowerska, N., McKenzie, D. R., & Reid, G. (2020). Covalent binding of molecules to plasma immersion ion implantation-activated microparticles for delivery into cells. Engineering Reports, 2, e12087. doi: 10.1002/eng2.12087

Journal - Research Other

van Zandwijk, N., Reid, G., & Baas, P. (2020). Emerging therapies for malignant mesothelioma. Frontiers in Oncology, 10, 939. doi: 10.3389/fonc.2020.00939

van Zandwijk, N., Reid, G., & Frank, A. L. (2020). Asbestos-related cancers: The ‘hidden killer’ remains a global threat. Expert Review of Anticancer Therapy, 20(4), 271-278. doi: 10.1080/14737140.2020.1745067

Reid, G., Johnson, T. G., & van Zandwijk, N. (2020). Manipulating microRNAs for the treatment of malignant pleural mesothelioma: Past, present and future. Frontiers in Oncology, 10, 105. doi: 10.3389/fonc.2020.00105

2019

Journal - Research Article

Kazantseva, M., Mehta, S., Eiholzer, R. A., Gimenez, G., Bowie, S., Campbell, H., Reily-Bell, A. L., … Ray, S., Drummond, C. J., Reid, G., … Wiles, A., Morrin, H. R., Reader, K. L., Hung, N. A., Baird, M. A., Slatter, T. L., & Braithwaite, A. W. (2019). The Δ133p53β isoform promotes an immunosuppressive environment leading to aggressive prostate cancer. Cell Death & Disease, 10, 631. doi: 10.1038/s41419-019-1861-1

Williams, M., Cheng, Y. Y., Kirschner, M. B., Sarun, K. H., Schlech, K., Winata, P., … Reid, G. (2019). Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma. Oncotarget, 10(41), 4125-4138. doi: 10.18632/oncotarget.27010

Ahmadzada, T., Lee, K., Clarke, C., Cooper, W. A., Linton, A., McCaughan, B., … Reid, G., & Kao, S. (2019). High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. Lung Cancer, 130, 35-41. doi: 10.1016/j.lungcan.2019.02.005

Conference Contribution - Published proceedings: Full paper

Johnson, T. G., Schelch, K., Mehta, S., Burgess, A., & Reid, G. (2019). Why be one protein when you can affect many? The multiple roles of YB-1 in lung cancer and mesothelioma. Frontiers in Cell & Developmental Biology, 7, 221. doi: 10.3389/fcell.2019.00221

Conference Contribution - Published proceedings: Abstract

Reid, G. (2019). Targeting altered microRNA expression in mesothelioma. Journal of Thoracic Oncology, 14(10), (pp. S18). doi: 10.1016/j.jtho.2019.08.077

Johnson, T., Schelch, K., Williams, M., Cheng, Y. Y., Grusch, M., Reid, G., & Burgess, A. (2019). Y-box binding protein-1, a potential target in malignant pleural mesothelioma, drives growth through distinct mechanisms. Journal of Thoracic Oncology, 14(10, Suppl.), (pp. S757). doi: 10.1016/j.jtho.2019.08.1624

2018

Journal - Research Article

Ahmadzada, T., Reid, G., & McKenzie, D. R. (2018). Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. Biophysical Reviews, 10(1), 69-86. doi: 10.1007/s12551-017-0392-1

Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., … TCGA Research Network, including Reid, G., … Ladanyi, M. (2018). Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discovery, 8(12), 1549-1565. doi: 10.1158/2159-8290.CD-18-0804

Johnson, T. G., Schelch, K., Cheng, Y. Y., Williams, M., Sarun, K. H., Kirschner, M. B., … Reid, G. (2018). Dysregulated expression of the microRNA miR-137 and its target YBX1 contribute to the invasive characteristics of malignant pleural mesothelioma. Journal of Thoracic Oncology, 13(2), 258-272. doi: 10.1016/j.jtho.2017.10.016

Rath, E. M., Cheng, Y. Y., Pinese, M., Sarun, K. H., Hudson, A. L., Weir, C., … Reid, G., … Church, W. B. (2018). BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state. PLoS ONE, 13(8), e0203003. doi: 10.1371/journal.pone.0203003

Schelch, K., Kirschner, M. B., Williams, M., Cheng, Y. Y., van Zandwijk, N., Grusch, M., & Reid, G. (2018). A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma. Molecular Oncology, 12(1), 58-73. doi: 10.1002/1878-0261.12150

Schelch, K., Wagner, C., Hager, S., Pirker, C., Siess, K., Lang, E., … Reid, G., … Hoda, M. A. (2018). FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. Carcinogenesis, 39(4), 534-545. doi: 10.1093/carcin/bgy018

Vafaee, F., Diakos, C., Kirschner, M. B., Reid, G., Michael, M. Z., Horvath, L. G., … Clarke, S. (2018). A data-driven, knowledge-based approach to biomarker discovery: Application to circulating microRNA markers of colorectal cancer prognosis. npj Systems Biology & Applications, 4, 20. doi: 10.1038/s41540-018-0056-1

Journal - Research Other

van Zandwijk, N., McDiarmid, J., Brahmbhatt, H., & Reid, G. (2018). Response to "An innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)". Translational Lung Cancer Research, 7(Suppl. 1), S60-S61. doi: 10.21037/tlcr.2018.01.11

Ahmadzada, T., Reid, G., & Kao, S. (2018). Biomarkers in malignant pleural mesothelioma: Current status and future directions. Journal of Thoracic Disease, 10, S1003-S1007. doi: 10.21037/jtd.2018.04.31

2017

Journal - Research Article

Cheng, Y. Y., Mok, E., Tan, S., Leygo, C., McLaughlin, C., George, A. M., & Reid, G. (2017). SFRP tumour suppressor genes are potential plasma-based epigenetic biomarkers for malignant pleural mesothelioma. Disease Markers, 2017, 2536187. doi: 10.1155/2017/2536187

Kao, S. C., Cheng, Y. Y., Williams, M., Kirschner, M. B., Madore, J., Lum, T., … Reid, G. (2017). Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. Journal of Thoracic Oncology, 12(9), 1421-1433. doi: 10.1016/j.jtho.2017.05.024

Kresoja-Rakic, J., Sulemani, M., Kirschner, M. B., Ronner, M., Reid, G., Kao, S., … Felley-Bosco, E. (2017). Posttranscriptional regulation controls calretinin expression in malignant pleural mesothelioma. Frontiers in Genetics, 8, 70. doi: 10.3389/fgene.2017.00070

van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., … Reid, G. (2017). Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncology, 18(10), 1386-1396. doi: 10.1016/S1470-2045(17)30621-6

Winata, P., Williams, M., McGowan, E., Nassif, N., van Zandwijk, N., & Reid, G. (2017). The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection. BMC Research Notes, 10, 600. doi: 10.1186/s13104-017-2930-0

Journal - Research Other

Robb, T., Reid, G., & Blenkiron, C. (2017). Exploiting microRNAs as cancer therapeutics. Targeted Oncology, 12(2), 163-178. doi: 10.1007/s11523-017-0476-7

Williams, M., Cheng, Y. Y., Blenkiron, C., & Reid, G. (2017). Exploring mechanisms of microRNA downregulation in cancer. MicroRNA, 6(1), 2-16. doi: 10.2174/2211536605666161208154633

2016

Journal - Research Article

Cheng, Y. Y., Wright, C. M., Kirschner, M. B., Williams, M., Sarun, K. H., Sytnyk, V., … Reid, G. (2016). KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. Molecular Cancer, 15, 44. doi: 10.1186/s12943-016-0529-z

Hoda, M. A., Dong, Y., Rozsas, A., Klikovits, T., Laszlo, V., Ghanim, B., … Reid, G., … Hegedus, B. (2016). Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma: A multi-institutional study. European Journal of Cancer, 63, 64-73. doi: 10.1016/j.ejca.2016.04.018

Kao, S. C., Kirschner, M. B., Cooper, W. A., Thran, T., Burgers, S., Wright, C., … Reid, G. (2016). A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. British Journal of Cancer, 114(5), 524-531. doi: 10.1038/bjc.2015.470

Journal - Research Other

Lin, R. C. Y., Kirschner, M. B., Cheng, Y. Y., van Zandwijk, N., & Reid, G. (2016). MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients. Genomics Data, 9, 44-49. doi: 10.1016/j.gdata.2016.06.009

Reid, G., Kao, S. C., Pavlakis, N., Brahmbhatt, H., MacDiarmid, J., Clarke, S., … van Zandwijk, N. (2016). Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer [Special report]. Epigenomics, 8(8), 1079-1085. doi: 10.2217/epi-2016-0035

van Zandwijk, N., Soeberg, M., & Reid, G. (2016). Using a multidisciplinary approach to combat the burden of asbestos-related disease: An update from the Asbestos Diseases Research Institute. Medical Journal of Australia, 204(2), 52-52.e1. doi: 10.5694/mja15.01209

2015

Chapter in Book - Research

Maher, S. G., Bibby, B. A. S., Moody, H. L., & Reid, G. (2015). MicroRNAs and cancer. In S. G. Gray (Ed.), Epigenetic cancer therapy. (pp. 67-90). Amsterdam, The Netherlands: Academic Press. doi: 10.1016/B978-0-12-800206-3.00004-5

Journal - Research Article

Birnie, K. A., Yip, Y. Y., Ng, D. C. H., Kirschner, M. B., Reid, G., Prêle, C. M., … Badrian, B. (2015). Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural mesothelioma. Molecular Cancer Research, 13(7), 1106-1118. doi: 10.1158/1541-7786.MCR-14-0442

Glover, A. R., Zhao, J. T., Gill, A. J., Weiss, J., Mugridge, N., Kim, E., … Reid, G., … Sidhu, S. B. (2015). microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. Oncotarget, 6(34), 36675-36688. doi: 10.18632/oncotarget.5383

Kirschner, M. B., Cheng, Y. Y., Armstrong, N. J., Lin, R. C. Y., Kao, S. C., Linton, A., … Reid, G. (2015). MiR-Score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Molecular Oncology, 9(3), 715-726. doi: 10.1016/j.molonc.2014.11.007

Kirschner, M. B., Pulford, E., Hoda, M. A., Rozsas, A., Griggs, K., Cheng, Y. Y., … Reid, G. (2015). Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. British Journal of Cancer, 113(6), 963-969. doi: 10.1038/bjc.2015.286

Klebe, S., Griggs, K., Cheng, Y., Driml, J., Henderson, D. W., & Reid, G. (2015). Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo model. Disease Markers, 2015, 286719. doi: 10.1155/2015/286719

Williams, M., Kirschner, M. B., Cheng, Y. Y., Hanh, J., Weiss, J., Mugridge, N., … Reid, G. (2015). miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget, 6(27), 23480-23495. doi: 10.18632/oncotarget.4346

Journal - Research Other

Kao, S. C., Fulham, M., Wong, K., Cooper, W., Brahmbhatt, H., MacDiarmid, J., … Reid, G., & van Zandwijk, N. (2015). A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. American Journal of Respiratory & Critical Care Medicine, 191(12), 1467-1469. doi: 10.1164/rccm.201503-0461LE

Reid, G. (2015). MicroRNAs in mesothelioma: From tumour suppressors and biomarkers to therapeutic targets. Journal of Thoracic Disease, 7(6), 1031-1040. doi: 10.3978/j.issn.2072-1439.2015.04.56

Intellectual Property

Reid, G., & van Zandwijk, N. (2015). MicroRNA-based approach to treating malignant pleural mesothelioma. (9,006,200). United States.

2014

Journal - Research Article

Cheng, N. C., van Zandwijk, N., & Reid, G. (2014). Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5. PLoS ONE, 9(3), e90374. doi: 10.1371/journal.pone.0090374

Linton, A., Cheng, Y. Y., Griggs, K., Kirschner, M. B., Gattani, S., Srikaran, S., … Reid, G. (2014). An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 110(2), 510-519. doi: 10.1038/bjc.2013.731

2013

Journal - Research Article

Cheng, Y. Y., Kirschner, M. B., Cheng, N. C., Gattani, S., Klebe, S., Edelman, J. J. B., … Reid, G. (2013). ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma. Journal of Thoracic Oncology, 8(10), 1317-1328. doi: 10.1097/JTO.0b013e3182a0840a

Kirschner, M. B., Edelman, J. J. B., Kao, S. C.-H., Vallely, M. P., van Zandwijk, N., & Reid, G. (2013). The impact of hemolysis on cell-free microRNA biomarkers. Frontiers in Genetics, 4, 94. doi: 10.3389/fgene.2013.00094

Lim, C. B., Prêle, C. M., Cheah, H. M., Cheng, Y. Y., Klebe, S., Reid, G., … Mutsaers, S. (2013). Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma. PLoS ONE, 8(6), e66685. doi: 10.1371/journal.pone.0066685

Reid, G., Pel, M. E., Kirschner, M. B., Cheng, Y. Y., Mugridge, N., Weiss, J., … van Zandwijk, N. (2013). Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma. Annals of Oncology, 24(12), 3128-3135. doi: 10.1093/annonc/mdt412

Wright, C. M., Kirschner, M. B., Cheng, Y. Y., O'Byrne, K. J., Gray, S. G., Schlech, K., … Reid, G. (2013). Long non coding RNAs (lncRNAs) are dysregulated in malignant pleural mesothelioma (MPM). PLoS ONE, 8(8), e70940. doi: 10.1371/journal.pone.0070940

Journal - Research Other

Henderson, D. W., Reid, G., Kao, S. C., van Zandwijk, N., & Klebe, S. (2013). Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. Journal of Clinical Pathology, 66(10), 854-861. doi: 10.1136/jclinpath-2013-201609

Henderson, D. W., Reid, G., Kao, S. C., van Zandwijk, N., & Klebe, S. (2013). Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. Journal of Clinical Pathology, 66(10), 847-853. doi: 10.1136/jclinpath-2012-201303

Kirschner, M. B., van Zandwijk, N., & Reid, G. (2013). Cell-free microRNAs: Potential biomarkers in need of standardized reporting. Frontiers in Genetics, 4, 56. doi: 10.3389/fgene.2013.00056

Wright, C. M., Kirschner, M. B., van Zandwijk, N., & Reid, G. (2013). Does miR-1 play a role in malignant pleural mesothelioma development and progression? Chest, 144(6), 1971. doi: 10.1378/chest.13-1657

2012

Journal - Research Article

Kirschner, M. B., Cheng, Y. Y., Badrian, B., Kao, S. C., Creaney, J., Edelman, J. J. B., … Reid, G. (2012). Increased circulating miR-625-3p: A potential biomarker for patients with malignant pleural mesothelioma. Journal of Thoracic Oncology, 7(7), 1184-1191. doi: 10.1097/JTO.0b013e3182572e83

2011

Journal - Research Article

Herbert, M., Coppieters, N., Lasham, A., Cao, H., & Reid, G. (2011). The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing. BMC Research Notes, 4, 148. doi: 10.1186/1756-0500-4-148

Kao, S. C.-H., Klebe, S., Henderson, D. W., Reid, G., Chatfield, M., Armstrong, N. J., … McCaughan, B. (2011). Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. Journal of Thoracic Oncology, 6(11), 1923-1929. doi: 10.1097/JTO.0b013e31822a3740

Kao, S. C. H., Lee, K., Armstrong, N. J., Clarke, S., Vardy, J., van Zandwijk, N., Reid, G., … Klebe, S. (2011). Validation of tissue microarray technology in malignantpleural mesothelioma. Pathology, 43(2), 128-132. doi: 10.1097/PAT.0b013e328342016c

Kirschner, M. B., Kao, S. C., Edelman, J. J., Armstrong, N. J., Vallely, M. P., van Zandwijk, N., & Reid, G. (2011). Haemolysis during sample preparation alters microRNA content of plasma. PLoS ONE, 6(9), e24145. doi: 10.1371/journal.pone.0024145

Li, Y., Revalde, J. L., Reid, G., & Paxton, J. W. (2011). Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. Cancer Chemotherapy & Pharmacology, 68(3), 603-610. doi: 10.1007/s00280-010-1515-6

Reid, G., Kirschner, M. B., & van Zandwijk, N. (2011). Circulating microRNAs: Association with disease and potential use as biomarkers. Critical Reviews in Oncology/Hematology, 80(2), 193-208. doi: 10.1016/j.critrevonc.2010.11.004

Journal - Research Other

Kao, S. C.-H., Reid, G., van Zandwijk, N., Henderson, D. W., & Klebe, S. (2011). Molecular biomarkers in malignant mesothelioma: State of the art [Invited]. Pathology, 43(3), 201-212. doi: 10.1097/PAT.0b013e3283445e67

2010

Journal - Research Other

Kao, S. C.-H., Reid, G., Lee, K., Vardy, J., Clarke, S., & van Zandwijk, N. (2010). Malignant mesothelioma. Internal Medicine Journal, 40(11), 742-750. doi: 10.1111/j.1445-5994.2010.02223.x

Li, Y., Revalde, J. L., Reid, G., & Paxton, J. W. (2010). Interactions of dietary phytochemicals with ABC transporters: Possible implications for drug disposition and multidrug resistance in cancer. Drug Metabolism Reviews, 42(4), 590-611. doi: 10.3109/03602531003758690

2009

Journal - Research Article

Lasham, A., Herbert, M., Coppieters t'Wallant, N., Patel, R., Feng, S., Eszes, M., … Reid, G. (2009). A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probe. Nucleic Acids Research, 38(3), e19. doi: 10.1093/nar/gkp1076

Patel, R., Coppieters t'Wallant, N., Herbert, M. H., White, D., Murison, J. G., & Reid, G. (2009). The potency of siRNA-mediated growth inhibition following silencing of essential genes is dependent on siRNA design and varies with target sequence. Oligonucleotides, 19(4), 317-328. doi: 10.1089/oli.2009.0207

2007

Journal - Research Article

Evseenko, D. A., Murthi, P., Paxton, J. W., Reid, G., Emerald, B. S., Mohankumar, K. M., … Keelan, J. A. (2007). The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. FASEB Journal, 21(13), 3592-3605. doi: 10.1096/fj.07-8688com

2005

Journal - Research Article

Wielinga, P., Hooijberg, J. H., Gunnarsdottir, S., Kathmann, I., Reid, G., Zelcer, N., … Borst, P. (2005). The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Research, 65(10), 4425-4430. doi: 10.1158/0008-5472.CAN-04-2810

2004

Journal - Research Article

Assem, M., Schuetz, E. G., Leggas, M., Sun, D., Yasuda, K., Reid, G., … Schuetz, J. D. (2004). Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. Journal of Biological Chemistry, 279(21), 22250-22257. doi: 10.1074/jbc.M314111200

Journal - Research Other

Borst, P., Balzarini, J., Ono, N., Reid, G., de Vries, H., Wielinga, P., … Zelcer, N. (2004). The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Research, 62(1), 1-7. doi: 10.1016/j.antiviral.2003.11.002

2003

Journal - Research Article

Reid, G., Wielinga, P., Zelcer, N., de Haas, M., van Deemter, L., Wijnholds, J., … Borst, P. (2003). Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Molecular Pharmacology, 63(5), 1094-1103. doi: 10.1124/mol.63.5.1094

Reid, G., Wielinga, P., Zelcer, N., van der Heijden, I., Kuil, A., de Haas, M., … Borst, P. (2003). The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. PNAS, 100(16), 9244-9249. doi: 10.1073/pnas.1033060100

Wielinga, P. R., van der Heijden, I., Reid, G., Beijnen, J. H., Wijnholds, J., & Borst, P. (2003). Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. Journal of Biological Chemistry, 278(20), 17664-17671. doi: 10.1074/jbc.M212723200

Wolff, N. A., Thies, K., Kuhnke, N., Reid, G., Friedrich, B., Lang, F., & Burckhardt, G. (2003). Protein kinase C activation downregulates human organic anion transporter 1-mediated transport through carrier internalization. Journal of the American Society of Nephrology, 14(8), 1959-1968. doi: 10.1097/01.ASN.0000079040.55124.25

Zelcer, N., Huisman, M. T., Reid, G., Wielinga, P., Breedveld, P., Kuil, A., … Borst, P. (2003). Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). Journal of Biological Chemistry, 278(26), 23538-23544. doi: 10.1074/jbc.M303504200

Zelcer, N., Reid, G., Wielinga, P., Kuil, A., van der Heijden, I., Schuetz, J. D., & Borst, P. (2003). Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochemical Journal, 371(2), 361-367. doi: 10.1042/BJ20021886

2002

Journal - Research Article

Adachi, M., Reid, G., & Schuetz, J. D. (2002). Therapeutic and biological importance of getting nucleotides out of cells: A case for the ABC transporters, MRP4 and 5. Advanced Drug Delivery Reviews, 54(10), 1333-1342. doi: 10.1016/S0169-409X(02)00166-7

Allen, J. D., van Loevezijn, A., Lakhai, L. M., van der Valk, M., van Tellingen, O., Reid, G., … Schinkel, A. H. (2002). Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C¹. Molecular Cancer Therapeutics, 1(6), 417-425.

Wielinga, P. R., Reid, G., Challa, E. E., van der Heijden, I., van Deemter, L., de Haas, M., … Borst, P. (2002). Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Molecular Pharmacology, 62(6), 1321-1331. doi: 10.1124/mol.62.6.1321

2001

Journal - Research Article

Zelcer, N., Saeki, T., Reid, G., Beijnen, J. H., & Borst, P. (2001). Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). Journal of Biological Chemistry, 276(49), 46400-46407. doi: 10.1074/jbc.M107041200

2000

Journal - Research Article

Bahn, A., Prawitt, D., Buttler, D., Reid, G., Enklaar, T., Wolff, N. A., … Burckhardt, G. (2000). Genomic structure and in vivo expression of the human organic anion transporter 1 (hOAT1) gene. Biochemical & Biophysical Research Communications, 275(2), 623-630. doi: 10.1006/bbrc.2000.3230

1999

Journal - Research Article

Edwards, A. M., Lyons, J., Weinberg, E., Weinberger, F., Gillies, J. D., Reid, G., … Isles, A. F. (1999). Early use of inhaled nedocromil sodium in children following an acute episode of asthma. Thorax, 54(4), 308-315.

1998

Journal - Research Article

Reid, G., Wolff, N. A., Dautzenberg, F. M., & Burckhardt, G. (1998). Cloning of a human renal p-aminohippurate transporter, hROAT1. Kidney & Blood Pressure Research, 21(2-4), 233-237. doi: 10.1159/000025863